We didn't set out to build an app. We set out to explain something that kept happening.

What we kept seeing

Over the past year, a pattern became hard to ignore — and it wasn't limited to one nationality. Teenagers. People in their twenties, thirties, and forties. Otherwise healthy, working expatriates, appearing in the news for the same reason: sudden cardiac arrest, no known diagnosis, no warning.

The clearest evidence came from an unexpected place: one expatriate community's own embassy. Tracking deaths among its nationals in a neighbouring Gulf country over an 18-month stretch, the mission found that between 50 and 72 percent were attributed to heart attack — and close to half of those affected in one emirate were under 40. If a single nationality's own diplomatic mission is recording numbers like that, the real, region-wide figure across every nationality is unlikely to be any lower.

Based on consular data reported in regional press. The figures are for one nationality's embassy; we treat them as an indicative regional signal, not a comprehensive multi-nationality study.

It isn't one group, and it isn't happening at the age it used to

This was never a story about a single nationality — the same shape repeats across many. What's changed is the age. Cardiovascular events clinicians once expected in someone's fifties or sixties now show up a generation earlier: one in five heart attacks today occur in adults 40 or younger, roughly double the share recorded just a decade ago.

Nearly half of adults in their twenties, thirties, and early forties already carry at least one major, modifiable cardiovascular risk factor — most without knowing it, because nothing in their routine ever tests for it.

So we asked: can everyday technology actually catch this?

That question already has an answer, and it's a well-documented one. When Stanford and Apple ran the largest study of its kind, over 400,000 people enrolled. Just 0.52% were ever flagged for an irregular heart rhythm — and of those who followed up with a week of ECG monitoring, more than a third turned out to have atrial fibrillation, a condition most had no idea they were carrying.

That was proof of concept for one condition, detected passively, at consumer scale. Nothing equivalent existed for the broader, everyday, modifiable cardiovascular risk behind most of these deaths — the kind a validated risk score can catch years before a scan would.

Then we looked at what it was already costing Qatar

The human pattern has a documented, local economic shadow. Non-communicable disease — with cardiovascular disease as the single largest driver — already accounts for 68% of all deaths in Qatar and costs the economy QAR 18.1 billion every year. Left unaddressed, a peer-reviewed projection puts the trajectory at QAR 71.1 billion in direct costs and QAR 108.1 billion in lost productivity between 2024 and 2033.

Insurers already feel this as claims, not just as a public-health statistic — and every conversation we've had with one confirms cardiac events are among the fastest-growing category on their books.

So we built Qalb Health

Qalb Health is a five-minute intake that becomes a continuously updated, clinically validated picture of your cardiovascular risk — followed by an engagement layer built to actually change what happens next, not just report a number and disappear.

In practice: a short set of clinical inputs — blood pressure, cholesterol, weight, smoking status, family history, and a few others — runs through the same validated scoring equations used in clinical practice, producing an actual risk percentage, not a vague "low, medium, high" label. That score drives everything downstream: a coaching plan in the person's own language, nudges timed to what's genuinely changeable — diet, activity, sleep, stress — and a re-assessment cadence, so the score updates as behaviour does instead of sitting static for a year.

What's already real, not just proposed

This isn't a concept waiting to be validated — the clinical foundation is built and reviewed today.

• Direct integration with the source, not a re-implementation of it. We're licensing the official AHA PREVENT calculation engine directly into our platform, so risk analysis runs on the same validated code its own authors maintain.

• ASCVD scoring alongside it. Two validated equations, cross-checked, not one model taken on faith.

• A cardiology advisory panel, including NHS-affiliated specialists, reviews the clinical approach.

• A firm boundary on AI. It handles coaching, engagement, and multilingual summaries — and is never involved in clinical scoring.

Who this is for, today

A free three-month pilot is the starting point for the first employers and insurers we work with.